There are currently 27 active clinical trials seeking participants for Malignant Neoplasm research studies. The states with the highest number of trials for Autism participants are Michigan, Nevada, Illinois and Minnesota.
Intraoperative Tumor Margin Identification With ICG Dye Imaging
NCT04752137
Recruiting
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Benign Neoplasm, Malignant Neoplasm
Register for Updates
Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
NCT02699697
Recruiting
This randomized phase II trial studies how well palliative radiation therapy works in reducing pain in patients with cancer that has spread from the original (primary) tumor to the bone (bone metastasis). Palliative radiation therapy using external beam radiation therapy may help patients with bone metastasis to relieve symptoms and reduce pain caused by cancer.
Gender:
All
Ages:
All
Trial Updated:
11/02/2023
Locations: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina
Conditions: Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone, Pain
Register for Updates
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Austin, Austin, Texas +3 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Platinum-resistant Ovarian Cancer, Cutaneous Squamous Cell Carcinoma
Register for Updates
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT05094804
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona +2 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Register for Updates
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT02479698
Recruiting
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Gender:
All
Ages:
All
Trial Updated:
10/25/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
Register for Updates
Patient-Derived Xenografts to Reduce Cancer Health Disparities
NCT04410302
Recruiting
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Gender:
All
Ages:
Between 21 years and 100 years
Trial Updated:
10/12/2023
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +1 locations
Conditions: Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
Register for Updates
New Assessment System in Measuring Symptom Distress in Cancer Patients
NCT00505245
Recruiting
This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Caregiver, Health Care Provider, Malignant Neoplasm, Physician
Register for Updates
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
All
Ages:
All
Trial Updated:
09/21/2023
Locations: Valleywise Comprehensive Health Center - Phoenix, Phoenix, Arizona +41 locations
Conditions: Malignant Neoplasm
Register for Updates
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
NCT03207854
Recruiting
This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.
Gender:
All
Ages:
19 years and above
Trial Updated:
08/09/2023
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Healthy Subject, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Neoplasm
Register for Updates
Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures
NCT03568292
Recruiting
This trial studies how well virtual reality (VR) works in reducing pain and anxiety in cancer participants undergoing bone marrow biopsy or lumbar puncture. Virtual reality may impact pain and anxiety during and after the procedure.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
08/09/2023
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Malignant Neoplasm
Register for Updates
18F-FMAU PET/CT in Imaging Patients With Advanced Cancers
NCT02079181
Recruiting
This clinical trial studies the safety and drug distribution of the radioactive drug, 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU [18F-FMAU]), for imaging with positron emission tomography/computed tomography (PET/CT) in patients with advanced cancers. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the g... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
08/09/2023
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Malignant Neoplasm
Register for Updates
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
NCT05082610
Recruiting
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: The City of Hope National Medical Center, Duarte, California +5 locations
Conditions: Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor
Register for Updates